Evidence map›Paper›PMID 33530129›Full record

ArticleStatistics in medicine2021

The length of the receiver operating characteristic curve and the two cutoff Youden index within a robust framework for discovery, evaluation, and cutoff estimation in biomarker studies involving improper receiver operating characteristic curves.

Leonidas E Bantis, John V Tsimikas, Gregory R Chambers, Michela Capello, Samir Hanash, Ziding Feng

Abstract read
In one paragraph

Article in Statistics in medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Leonidas E BantisDepartment of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.ORCID 0000-0002-2364-2562
John V TsimikasDepartment of Statistics and Actuarial-Financial Mathematics, University of the Aegean, Samos, Greece.
Gregory R ChambersDepartment of Mathematics, Rice University, Houston, Texas, USA.
Michela CapelloDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Samir HanashDepartment of Clinical Cancer Prevention, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Ziding FengDepartment of Biostatistics, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.

Funding

The Early Detection Research Network: Data Management and Coordinating CenterU24CA086368 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI RUTH D ETZIONI, Ziding Feng · 2010 to 2026
$75.7M
RADx-UP: Improving the Response of Local Urban and Rural Communities to Disparities in Covid-19 TestingUL1TR002366 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Mario Castro, JAMES STEVEN LEEDER · 2017 to 2026
$44.3M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ANDREW K. GODWIN · 2019 to 2026
$21.5M
NCATS NIH HHS UL1 TR002366NCI NIH HHS U24 CA086368NIGMS NIH HHS P20 GM130423
6 · The paper itself

Abstract

During the early stage of biomarker discovery, high throughput technologies allow for simultaneous input of thousands of biomarkers that attempt to discriminate between healthy and diseased subjects. In such cases, proper ranking of biomarkers is highly important. Common measures, such as the area under the receiver operating characteristic (ROC) curve (AUC), as well as affordable sensitivity and specificity levels, are often taken into consideration. Strictly speaking, such measures are appropriate under a stochastic ordering assumption, which implies, without loss of generality, that higher measurements are more indicative for the disease. Such an assumption is not always plausible and may lead to rejection of extremely useful biomarkers at this early discovery stage. We explore the length of a smooth ROC curve as a measure for biomarker ranking, which is not subject to directionality. We show that the length corresponds to a

Indexed as

ROC CurveArea Under CurveBiomarkersSensitivity and SpecificityBiomarkersisoperimetrickernelslikelihood ratiooptimal ROCsensitivityspecificitystochastic orderingtwo-cutoff ROCYouden

Identifiers

PMID33530129
PMCPMC9976806

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.